Alcohol Biomarkers In Post Liver Transplant Patients

描述（由申请人提供）：这个职业中期K24申请的目标是支持迈克尔·弗莱明博士的指导和研究活动。他致力于在临床和转化研究方面继续积极的研究项目。这项赠款是一项竞争性续期，最初于2005年9月资助，将于2010年9月结束。他要求追加5年的资金。弗莱明博士成功完成了最初申请中提出的两项研究，并参加了培训活动，指导博士生、博士后和教职员工。在获奖期间，他被选为国家科学院医学研究所的酒精研究和指导。他也是CTSA（临床转化科学奖）项目的国家领导者，也是国家CTSA教育关键功能委员会和导师工作组的主席。目前K24资助完成的工作：第一项研究评估了214例创伤患者的两种酒精生物标志物，血液酒精水平和碳水化合物缺乏转铁蛋白（CDT）。第二项研究测试了哌甲酯对13名被诊断为注意力缺陷障碍和胎儿酒精谱系障碍的儿童的疗效。自2005年以来，他的研究小组和学员在药物滥用领域发表了42篇研究论文。这些论文的共同作者包括5名学生，9名医生博士后研究员，11名威斯康星大学麦迪逊分校的医生教师和12个非威斯康星大学研究小组的科学家。在过去四年中，他的六名学员获得了K23/K08/K12/K01/R21/R03奖学金，一名医学博士研究生获得了F30奖学金，另一名博士研究生获得了F31奖学金。如果没有K24基金提供的工资和研究支持，他的大部分工作和学员的成功是不可能的。K24更新的建议工作：K24更新将为弗莱明博士提供保护时间，以指导医学，儿科和家庭医学部门的七名助理教授，并促进他与最近完成的三个R01的学员一起撰写论文的能力。他还将启动一项前瞻性酒精生物标志物研究，在250名肝移植后患者的样本中测试磷脂酰乙醇（PEth）和CDT的预测有效性和可靠性。受试者将从四个移植中心招募。这些生物标志物将与患者自我报告、家属访谈、移植工作人员关注的问题以及医疗记录数据进行比较。在一年的时间里，每隔六个月测量一次PEth和CDT。意义：K24对弗莱明博士继续指导酒精研究的新研究者以及他对酒精生物标志物的研究至关重要。

DESCRIPTION (provided by applicant): The goal of this mid-career K24 application is to support the mentoring and research activities of Dr. Michael Fleming. He is committed to continuing an active research program in clinical and translational research. This grant is a competitive renewal that was initially funded in September 2005 and will end in September 2010. He is asking for an additional 5 years of funding. Dr. Fleming successfully completed the two research studies proposed in the initial application, participated in training activities and mentored PhD students, post doctoral fellows and faculty. During the period of the award he was elected to the National Academy of Sciences Institute of Medicine for his alcohol research and mentoring. He is also a national leader among the CTSA (Clinical Translational Science Award) programs and is the chair elect of the national CTSA Education Key Function Committee and Mentor Working Group. Work completed with current K24 grant: The first study evaluated two alcohol biomarkers, Blood Alcohol Levels and Carbohydrate-Deficient Transferrin (CDT), in a sample 214 patients admitted for trauma. The second study tested the efficacy of methylphenidate in a sample 13 children with a diagnosis of Attention Deficit Disorder and Fetal Alcohol Spectrum Disorder. Since 2005 his research group and trainees have published 42 research papers in the substance abuse area. Co-authors of these papers include five students, nine physician post doctoral research fellows, 11 University of Wisconsin-Madison physician faculty and scientists from 12 non-UW research groups. Over the last four years six of his trainees have been awarded K23/K08/K12/K01/R21/R03 grants, one MD PhD student was awarded an F30 and another PhD student an F31 grant. Without the salary and research support provided by the K24 grant much of this work and the success of his trainees would not have been possible. Proposed work for the K24 renewal: The K24 renewal will provide protected time for Dr. Fleming to mentor seven assistant professors in the departments of medicine, pediatrics and family medicine and facilitate his ability to write papers with trainees from three recently completed R01's. He will also initiate a prospective alcohol biomarker study that will test the predictive validity and reliability of Phosphatidylethanol (PEth) and CDT in a sample of 250 post liver transplant patients. Subjects will be recruited from four transplant centers. The biomarkers will be compared to patient self-report, family member interview and transplant staff concerns as well as medical records data. PEth and CDT will be measured at six-month intervals for one year. Significance: The K24 is critical for Dr. Fleming's continued ability to mentor new investigators in alcohol research and for his research on alcohol biomarkers. PUBLIC HEALTH RELEVANCE: The goal of the study is to find out if a lab test can tell which patients are drinking alcohol after having a liver transplant. A positive study would help physicians identify and treat patients before they damage their new liver.